No records
|
657 |
Irawan C., Benbella L.G., Rachman A., Mansjoer A. |
28767651600;57357413600;15056701600;24335647800; |
Factors that Influence 2-Year Progression-Free Survival Among Head and Neck Cancer Patients |
2021 |
Journal of Epidemiology and Global Health |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120335157&doi=10.1007%2fs44197-021-00016-2&partnerID=40&md5=eae0237d32c525daedf560529a50ad64 |
Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jl. Diponegoro no. 71, Jakarta, 10430, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia; Cardiology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia |
Irawan, C., Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jl. Diponegoro no. 71, Jakarta, 10430, Indonesia; Benbella, L.G., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia; Rachman, A., Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jl. Diponegoro no. 71, Jakarta, 10430, Indonesia; Mansjoer, A., Cardiology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia |
Objectives: The majority of patients with head and neck cancer (HNC) come to the hospital at advanced stages. This research was conducted to determine the mortality, 2-year progression-free survival (PFS) and factors that influenced PFS of HNC patients. Methods: A retrospective cohort study was conducted among locally advanced HNC patients who underwent chemoradiation for the first time at RSCM from January 2015 to December 2017. Data were retrieved through medical records. Laboratory data were taken 2–4 weeks prior and 2–4 weeks after chemoradiation. PFS observation started from the first day of chemoradiation until disease progression or death. PFS data were recorded in two groups: ≤ 2 years and > 2 years. The Chi-square test was used for bivariate analysis with the Fischer-exact test as an alternative. Variables will be further tested using multivariate logistic regression tests. Results: Among 216 subjects, there were 103 (47.69%) patients who did not reach overall survival (OS) > 2 years. There were 108 (50%) patients who had PFS > 2 years. Based on the results of multivariate analysis, it was found that smoking, hemoglobin level ≤ 12 g/dl, ECOG (Eastern Cooperative Oncology Group) 1–2, and negative therapeutic response were associated with poor PFS. Hazard ratio (HR) for 2-year PFS for Brinkman index > 250 was 1.36 (95% CI 0.93–2.00; p = 0.02); HR for Hb ≤ 12 g/dl was 1.65 (95% CI 1.13–2.42; p = 0.01); HR for ECOG 1–2 was 4.05 (95% CI 1.49–11.00; p < 0.01); and HR for negative therapeutic response was 2.37 (95% CI 1.43–3.94; p < 0.01). Conclusion: Mortality of HNC patients within 2 years is 47.69%, with a 2-year PFS reaching 50%. Cigarette smoking, low hemoglobin levels, poor performance status, and negative therapeutic response (non-responders) negatively affect the 2-year PFS. © 2021, The Author(s). |
Factor; Head and neck cancer; Mortality; Progression-free survival |
|
Atlantis Press |
22106006 |
|
|
Article |
Q3 |
665 |
7531 |
|
|
658 |
Gatam A.R., Gatam L., Mahadhipta H., Ajiantoro A., Luthfi O., Aprilya D. |
57189987623;57197708604;57210642162;57357077400;57356571700;57193710642; |
Unilateral biportal endoscopic lumbar interbody fusion: A technical note and an outcome comparison with the conventional minimally invasive fusion |
2021 |
Orthopedic Research and Reviews |
13 |
|
|
229 |
239 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120168036&doi=10.2147%2fORR.S336479&partnerID=40&md5=975bbbda77330a970b9d9c16d7f501be |
Orthopaedic Spine Division, Fatmawati General Hospital, Jakarta, Indonesia; Orthopaedic Spine Division, Tangerang General Hospital, Banten, Indonesia; Orthopaedic Spine Division, Premier Bintaro Hospital, Banten, Indonesia; Orthopedic Spine Division, Adhyaksa General Hospital, Jakarta, Indonesia; Orthopedic and Traumatology Department, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia |
Gatam, A.R., Orthopaedic Spine Division, Fatmawati General Hospital, Jakarta, Indonesia; Gatam, L., Orthopaedic Spine Division, Fatmawati General Hospital, Jakarta, Indonesia; Mahadhipta, H., Orthopaedic Spine Division, Tangerang General Hospital, Banten, Indonesia; Ajiantoro, A., Orthopaedic Spine Division, Premier Bintaro Hospital, Banten, Indonesia; Luthfi, O., Orthopedic Spine Division, Adhyaksa General Hospital, Jakarta, Indonesia; Aprilya, D., Orthopedic and Traumatology Department, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia |
Background: In the past few decades, the minimally invasive technique for spine surgery has developed extensively from the scope of decompression until fusion surgeries to reduce damages to the normal anatomical structure. Unilateral biportal endoscopic lumbar interbody fusion (ULIF) is one of the fusion options which is readily available without a sophisticated minimal invasive instrument. Our aim is to introduce ULIF experience in our center and comparing the result with conventional minimally invasive lumbar interbody fusion (MIS-TLIF). Methods: This is a retrospective cohort study of 145 lumbar spondylolisthesis cases that underwent fusion surgery with either ULIF or the conventional MIS-TLIF. All of the patients were observed within a 12-month follow-up period to evaluate the back pain and leg pain Visual Analogue Score (VAS), the Oswestry Disability Index (ODI), the 36-Item Short Form Health Survey (SF-36), and fusion rate. Results: The leg pain VAS was similarly improved in both groups. ULIF has a significant back pain improvement on direct post operation and at the 3-months follow-up (p value 0.032 and 0.046 respectively). ULIF group also had a significantly better improvement of ODI scores on the early post-operative period (p=0.045). However, both groups similarly showed improvement of ODI score and the SF-36 at the 3-, 6-, and 12-months follow up. Conclusion: Full endoscopic fusion surgery with ULIF offers a comparable long-term outcome and a significantly better back pain VAS reduction in short-term follow up compared to the conventional MIS-TLIF. ULIF, with further improvement, can be the next gold standard in managing degenerative lumbar spine conditions. © 2021 Gatam et al. |
Degenerative spondylolisthesis; Full endoscopic spine surgery; Lumbar interbody fusion; Lumbar spine; Minimally invasive spine surgery; MISS; Unilateral biportal endoscopy |
|
Dove Medical Press Ltd |
11791462 |
|
|
Article |
Q2 |
707 |
7037 |
|
|
659 |
Dewi S., Yulhasri Y., Mulyawan W. |
57192904541;57225180520;57192910410; |
The Impact of Intermittent Hypobaric Hypoxia Exposures on Triacylglycerol Synthesis in Rat Liver |
2021 |
Reports of Biochemistry and Molecular Biology |
10 |
3 |
|
437 |
444 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120058392&partnerID=40&md5=0ff2179c774f4a9d0d0a1c462ec80dc4 |
Department of Biochemistry and Molecular Biology, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Center of Hypoxia and Oxidative Stress Studies, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Department of Aerophysiology, Lakespra Saryanto, Air Force Indonesian National Army, Jakarta, Indonesia |
Dewi, S., Department of Biochemistry and Molecular Biology, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Center of Hypoxia and Oxidative Stress Studies, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Yulhasri, Y., Department of Biochemistry and Molecular Biology, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Center of Hypoxia and Oxidative Stress Studies, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Mulyawan, W., Department of Aerophysiology, Lakespra Saryanto, Air Force Indonesian National Army, Jakarta, Indonesia |
Background: In a hypoxic state, fatty acid breakdown reaction may be inhibited due to a lack of oxygen. It is likely that the fatty acids will be stored as triacylglycerol. The aim of this study was to analyse triacylglycerol synthesis in the liver after intermittent hypobaric hypoxia (HH) exposures. Methods: Samples are liver tissues from 25 male Wistar rats were divided into 5 groups: controlgroup (normoxia), group I (once HH exposure), group II (twice HH exposures), group III (three-times HH exposures) and group IV (four-times HH exposures). The triacylglycerol level, mRNA expression of HIF-1α and PPAR-γ were measured in rat liver from each group.Results: We demonstrated that triacylglycerol level, mRNA expression of HIF-1α and PPAR-γ is elevated in group I significantly compared to control group. In the intermittent HH groups (group II, III and IV), mRNA expression of HIF-1α and PPAR-γ tends to downregulate near to control group. However, the triacylglycerol level is still found increased in the intermittent HH exposures groups. Significant increasing of triacylglycerol level was found especially in group IV compared to control group.Conclusions: We conclude that intermittent HH exposures will increase the triacylglycerol level in rat liver, supported by the increasing of HIF-1α and PPAR-γ mRNA expression that act as transcription factor to promote triacylglycerol synthesis © 2021. Reports of Biochemistry & Molecular Biology. All Rights Reserved. |
HIF-1α; Hypoxia; Liver; PPAR-γ; Triacylglycerol |
|
Varastegan Institute for Medical Sciences |
23223480 |
|
|
Article |
Q3 |
467 |
10677 |
|
|
660 |
Ramani S., McKimm J., Forrest K., Hays R., Bishop J., Thampy H., Findyartini A., Nadarajah V.D., Kusurkar R., Wilson K., Filipe H., Kachur E. |
56186462600;26433565200;26635053400;7202509928;8406026800;55349958700;56543777300;14048599600;6603461994;56926010000;36657108400;6603938626; |
Co-creating scholarship through collaborative writing in health professions education: AMEE Guide No. 143 |
2021 |
Medical Teacher |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120044813&doi=10.1080%2f0142159X.2021.1993162&partnerID=40&md5=3773bd230107ba738a15f75175eba901 |
Harvard Medical School, Boston, United States; Manchester Medical School, University of Manchester, Manchester, United Kingdom; Swansea University Medical School, United Kingdom; Bond University, Queensland, Australia; James Cook University College of Medicine and Dentistry, James Cook University, Townsville, Australia; Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; International Medical University, Kuala Lumpur, Malaysia; Amsterdam UMC, Research in Education, Faculty of Medicine, Vrije Universiteit, Amsterdam, Netherlands; Dalhousie University, Halifax, NS, Canada; Hospital Egas Moniz, West Lisbon Hospitals Center (NHS), University of Lisbon, Lisboa, Portugal; Medical Education Development, Global Consulting, New York, NY, United States |
Ramani, S., Harvard Medical School, Boston, United States, Manchester Medical School, University of Manchester, Manchester, United Kingdom; McKimm, J., Swansea University Medical School, United Kingdom; Forrest, K., Bond University, Queensland, Australia; Hays, R., James Cook University College of Medicine and Dentistry, James Cook University, Townsville, Australia; Bishop, J., Bond University, Queensland, Australia; Thampy, H., Manchester Medical School, University of Manchester, Manchester, United Kingdom; Findyartini, A., Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Nadarajah, V.D., International Medical University, Kuala Lumpur, Malaysia; Kusurkar, R., Amsterdam UMC, Research in Education, Faculty of Medicine, Vrije Universiteit, Amsterdam, Netherlands; Wilson, K., Dalhousie University, Halifax, NS, Canada; Filipe, H., Hospital Egas Moniz, West Lisbon Hospitals Center (NHS), University of Lisbon, Lisboa, Portugal; Kachur, E., Medical Education Development, Global Consulting, New York, NY, United States |
This AMEE guide provides a robust framework and practical strategies for health professions educators to enhance their writing skills and engage in successful scholarship within a collaborative writing team. Whether scholarly output involves peer-reviewed articles, book chapters, blogs and online posts, online educational resources, collaborative writing requires more than the usual core writing skills, it requires teamwork, leadership and followership, negotiation, and conflict resolution, mentoring and more. Whilst educators can attend workshops or courses to enhance their writing skills, there may be fewer opportunities to join a community of scholars and engage in successful collaborative writing. There is very little guidance on how to find, join, position oneself and contribute to a writing group. Once individuals join a group, further questions arise as to how to contribute, when and whom to ask for help, whether their contribution is significant, and how to move from the periphery to the centre of the group. The most important question of all is how to translate disparate ideas into a shared key message and articulate it clearly. In this guide, we describe the value of working within a collaborative writing group; reflect on principles that anchor the concept of writing as a team and guide team behaviours; suggest explicit strategies to overcome challenges and promote successful writing that contributes to and advances the field; and review challenges to starting, maintaining, and completing writing tasks. We approach writing through three lenses: that of the individual writer, the writing team, and the scholarly product, the ultimate goal being meaningful contributions to the field of Health Professions Education. © 2021 AMEE. |
collaborative/peer-to-peer; Continuing; leadership; mentoring; staff development |
|
Taylor and Francis Ltd. |
0142159X |
|
|
Article |
Q1 |
1355 |
2689 |
|
|
661 |
Andreas A.M., Djuwita R., Helda H., Sekartni R., Suradijono S.H.R., Wiguna T., Tulaar A.B.M., Kristianto Y., Hendrik H. |
57356220700;56586138300;57195467249;57355240300;57209473358;57356086800;24330360800;57356220800;57355801600; |
Massage therapy can prevent the risk of autism spectrum disorders in children |
2021 |
Open Access Macedonian Journal of Medical Sciences |
9 |
|
|
1556 |
1560 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120032396&doi=10.3889%2foamjms.2021.7436&partnerID=40&md5=ca9744bb24e561c7ddfc3916dd11ecc2 |
Faculty of Public Health, University of Indonesia, Jakarta, Indonesia; Department of Pediatrics and Development, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Developmental Psychology, Faculty of Psychology, University of Indonesia, Jakarta, Indonesia; Department of Child Psychiatry, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Medical Rehabilitation, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Health Polytechnic, Ministry of Health Jakarta 1, Jakarta, Indonesia; Department of Physiotherapy, Health Polytechnic, Ministry of Health Makassar, Makassar, Indonesia |
Andreas, A.M., Faculty of Public Health, University of Indonesia, Jakarta, Indonesia; Djuwita, R., Faculty of Public Health, University of Indonesia, Jakarta, Indonesia; Helda, H., Faculty of Public Health, University of Indonesia, Jakarta, Indonesia; Sekartni, R., Department of Pediatrics and Development, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Suradijono, S.H.R., Department of Developmental Psychology, Faculty of Psychology, University of Indonesia, Jakarta, Indonesia; Wiguna, T., Department of Child Psychiatry, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Tulaar, A.B.M., Department of Medical Rehabilitation, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Kristianto, Y., Health Polytechnic, Ministry of Health Jakarta 1, Jakarta, Indonesia; Hendrik, H., Department of Physiotherapy, Health Polytechnic, Ministry of Health Makassar, Makassar, Indonesia |
BACKGROUND: The prevalence of human beings with autism spectrum issues in some parts of the world tends to make bigger, in Indonesia alone, accurate and complete data and information from human beings with autism spectrum disorders (ASD) are nonetheless missing, so it is feared that many children with risk symptoms of ASD do not get treatment early. AIM: This research aims to prevent the risk of ASD in children through making use of massage therapy remedies based on evaluation of the Modified Checklist for Autism in Toddler (modified Chat [M-Chat]) ratings. METHODS: This research is a quasi-experimental study with a time series design which was carried out from May 2019 to March 2020 at three health centers in the city of Jakarta. The analysis was carried out before and after the application of massage in a time series of four periods on ten children aged 18–36 months with M-Chat scores, and then analyzed by receiver operating characteristics to obtain a cutoff point to determine the risk status of ASD. RESULTS: The results showed that there was an effect of massage therapy on the M-Chat score of children with ASD risk p = 0.004 < 0.05 and changes in the M-Chat score of children with ASD risk experienced significant changes after massage in the third and fourth therapy periods with p = 0.005 and p = 0.007 < 0.05. CONCLUSION: The results show that massage therapy can prevent of autism spectrum issues in children based on the Modified Checklist for Autism in Toddler (M-Chat). © 2021 Andy Martahan Andreas, Ratna Djuwita, Helda Helda, Rini Sekartni, Sri Hartati R. Suradijono, Thjin Wiguna, Angela B. M. Tulaar, Yusuf Kristianto, Hendrik Hendrik. |
Autism spectrum disorders; Babies; Massage therapy; Modified checklist for autism in toddler |
Article; autism; cesarean section; checklist; child; chromosome aberration; female; health center; human; human experiment; Indonesia; male; massage; pH; predictive value; preschool child; prevalence; prospective study; QT interval; quasi experimental study; receiver operating characteristic; scoring system; sensitivity and specificity; time series analysis; toddler |
Scientific Foundation SPIROSKI |
18579655 |
|
|
Article |
Q3 |
288 |
15252 |
|
|
662 |
Ta J.W.C., Chew D.P., Tsui K.L., Tan D., Duplyakov D., Hammoudeh A., Zhang B., Li Y., Xu K., Ong P.J., Firman D., Gamra H., Almahmeed W., Dalal J., Tam L.-W., Steg G., Nguyen Q.N., Ako J., Al Suwaidi J., Chan M., Sobhy M., Shehab A., Buddhari W., Wang Z., Fong A.Y.Y., Karadag B., Kim B.-K., Baber U., Chin C.T., Han Y.L. |
57354736300;7102026332;7101671562;50263435900;6506125408;8088443300;56637270100;55914058500;56510776700;7102312670;54898724100;7004594521;6506558682;7004278395;56585509700;57197860836;39962151600;6701389098;6603728555;23388249600;55345664600;6603838351;57192991797;8875501800;14321654600;56243107600;35189204900;16047315200;57226594604;57211831338; |
2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations |
2021 |
European Cardiology Review |
16 |
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119968735&doi=10.15420%2fecr.2021.35&partnerID=40&md5=0f474aea7166811035b920e727476fae |
National Heart Centre, Singapore; Sengkang General Hospital, Singapore; College of Medicine and Public Health, Flinders University, Adelaide, Australia; Pamela Youde Nethersole Eastern Hospital, Hong Kong; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Samara Regional Cardiology Dispensary, Samara, Russian Federation; Cardiology Department, Istishari Hospital, Amman, Jordan; Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore; Tan Tock Seng Hospital, Singapore; Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Cleveland Clinic Abu Dhabi, United Arab Emirates; Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Kwong Wah Hospital, Hong Kong; Department of Cardiology, Hôpital Bichat, Paris, France; Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; National University Heart Centre, Singapore; Faculty of Medicine, Alexandria University, Egypt; College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Sarawak Heart Centre, Kota Samarahan, Malaysia; Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States |
Ta, J.W.C., National Heart Centre, Singapore, Sengkang General Hospital, Singapore; Chew, D.P., College of Medicine and Public Health, Flinders University, Adelaide, Australia; Tsui, K.L., Pamela Youde Nethersole Eastern Hospital, Hong Kong; Tan, D., Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Duplyakov, D., Samara Regional Cardiology Dispensary, Samara, Russian Federation; Hammoudeh, A., Cardiology Department, Istishari Hospital, Amman, Jordan; Zhang, B., Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Li, Y., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Xu, K., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Ong, P.J., Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore, Tan Tock Seng Hospital, Singapore; Firman, D., Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Gamra, H., Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Almahmeed, W., Cleveland Clinic Abu Dhabi, United Arab Emirates; Dalal, J., Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Tam, L.-W., Kwong Wah Hospital, Hong Kong; Steg, G., Department of Cardiology, Hôpital Bichat, Paris, France; Nguyen, Q.N., Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Ako, J., Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Al Suwaidi, J., Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; Chan, M., National University Heart Centre, Singapore; Sobhy, M., Faculty of Medicine, Alexandria University, Egypt; Shehab, A., College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; Buddhari, W., King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Wang, Z., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Fong, A.Y.Y., Sarawak Heart Centre, Kota Samarahan, Malaysia; Karadag, B., Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Kim, B.-K., Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; Baber, U., University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Chin, C.T., National Heart Centre, Singapore; Han, Y.L., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China |
Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have displayed characteristics that are clinically distinct from Western patients. Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y12inhibitors (i.e. ticagrelor and prasugrel) after acute coronary syndromes (ACS) in Asia. The authors summarise evidence on the use of these P2Y12inhibitors during the transition from ACS to CCS and among special populations. Specifically, they present recommendations on the roles of standard dual antiplatelet therapy, shortened dual antiplatelet therapy and single antiplatelet therapy among patients with coronary artery disease, who are either transitioning from ACS to CCS; elderly; or with chronic kidney disease, diabetes, multivessel coronary artery disease and bleeding events during therapy. © 2021 Radcliffe Group Ltd. All rights reserved. |
Asia; Comorbidity; Consensus; Dual antiplatelet therapy; Myocardial ischaemia; Platelet aggregation inhibitors |
|
Radcliffe Medical Media |
17583756 |
|
|
Article |
Q2 |
864 |
5422 |
|
|
664 |
Han W.M., Law M.G., Choi J.Y., Ditangco R., Kumarasamy N., Chaiwarith R., Ly P.S., Khusuwan S., Merati T.P., Do C.D., Yunihastuti E., Azwa I., Lee M.-P., Pham T.N., Chan Y.-J., Kiertiburanakul S., Ng O.T., Tanuma J., Pujari S., Zhang F., Gani Y., Mave V., Ross J., Avihingsanon A., Ly P.S., Khol V., Zhang F.J., Zhao H.X., Han N., Lee M.P., Li P.C.K., Kwong T.S., Li T.H., Kumarasamy N., Ezhilarasi C., Pujari S., Joshi K., Gaikwad S., Chitalikar A., Sangle S., Mave V., Marbaniang I., Nimkar S., Merati T.P., Wirawan D.N., Yuliana F., Yunihastuti E., Widhani A., Maria S., Karjadi T.H., Tanuma J., Oka S., Nishijima T., Choi J.Y., Na S., Kim J.M., Gani Y.M., Rudi N.B., Azwa I., Kamarulzaman A., SyedOmar S.F., Ponnampalavanar S., Ditangco R., Pasayan M.K., Mationg M.L., Chan Y.J., Ku W.W., Wu P.C., Ke E., Ng O.T., Lim P.L., Lee L.S., Yap T., Ng O.T., Avihingsanon A., Gatechompol S., Phanuphak P., Phadungphon C., Kiertiburanakul S., Phuphuakrat A., Chumla L., Sanmeema N., Chaiwarith R., Sirisanthana T., Praparattanapan J., Nuket K., Khusuwan S., Payoong P., Kantipong P., Kambua P., Pham T.N., Nguyen K.V., Nguyen D.T.H., Nguyen D.T., Do C.D., Ngo A.V., Nguyen L.T., Sohn A.H., Ross J.L., Petersen B., Law M.G., Jiamsakul A., Rupasinghe D., the TREAT Asia HIV Observational Database of IeDEA Asia-Pacific |
57201984684;55556254800;57316129500;55406840800;7003549856;13806165200;9743902800;56166613100;57203678680;56658396600;57221273925;55553159100;57309539000;57213330022;33667461800;6506539792;57350864400;57211702929;57205894660;23007277900;57188842533;24778446900;57193109926;57196347321;57204852770;57188842644;55503803800;35796801900;57206253688;56143671100;57203375227;57350625400;57351089100;55412491000;55413091200;57213607670;35227451500;55273903300;57188839029;6602877716;57425871800;57189801547;56820043000;8935806500;6601921496;57202976978;8850357600;57202561455;57213345044;57219422563;57208428839;57202558648;57226409961;48761023600;57351205400;7601387767;57188842533;57257789600;55553159100;6603019663;55866927600;36768852500;57258598000;57207954173;36936083900;57258255400;55856943500;56514424400;57257813200;57215769524;57210531225;55992506400;57351089200;57203665233;57200282477;57193906863;7004982661;56015716600;57203677438;8277552900;56515326900;55992497800;57203665049;7004277229;35185428900;57192871045;56166613100;57350625500;6603580797;55285745100;57224761710;56370854300;57190300831;56970337500;55035577700;57208054163;41961438300;7006405275;57193720576;56406054800;57222965808;55285745500;57205313395; |
Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV |
2021 |
HIV Medicine |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119685299&doi=10.1111%2fhiv.13211&partnerID=40&md5=043ac7a37890286dc2e8fb917b3e95bc |
The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Research Institute for Tropical Medicine, Muntinlupa City, Philippines; Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS Infectious Diseases Medical Centre, VHSChennai, India; Chiang Mai University – Research Institute for Health Sciences, Chiang Mai, Thailand; National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; Faculty of Medicine, Udayana University & Sanglah Hospital, Bali, Indonesia; Bach Mai Hospital, Hanoi, Viet Nam; Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; University Malaya Medical Centre, Kuala Lumpur, Malaysia; Queen Elizabeth Hospital, Hong Kong; National Hospital for Tropical Diseases, Hanoi, Viet Nam; Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore; National Center for Global Health and Medicine, Tokyo, Japan; Institute of Infectious Diseases, Pune, India; Beijing Ditan Hospital, Capital Medical University, Beijing, China; Hospital Sungai Buloh, Sungai Buloh, Malaysia; BJ Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India; TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand; Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand |
Han, W.M., The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; Law, M.G., The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; Choi, J.Y., Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Ditangco, R., Research Institute for Tropical Medicine, Muntinlupa City, Philippines; Kumarasamy, N., Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS Infectious Diseases Medical Centre, VHSChennai, India; Chaiwarith, R., Chiang Mai University – Research Institute for Health Sciences, Chiang Mai, Thailand; Ly, P.S., National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Khusuwan, S., Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand, ; Merati, T.P., Faculty of Medicine, Udayana University & Sanglah Hospital, Bali, Indonesia; Do, C.D., Bach Mai Hospital, Hanoi, Viet Nam; Yunihastuti, E., Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Azwa, I., University Malaya Medical Centre, Kuala Lumpur, Malaysia, ; Lee, M.-P., Queen Elizabeth Hospital, Hong Kong; Pham, T.N., National Hospital for Tropical Diseases, Hanoi, Viet Nam; Chan, Y.-J., Taipei Veterans General Hospital, Taipei, Taiwan; Kiertiburanakul, S., Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Ng, O.T., Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore; Tanuma, J., National Center for Global Health and Medicine, Tokyo, Japan; Pujari, S., Institute of Infectious Diseases, Pune, India; Zhang, F., Beijing Ditan Hospital, Capital Medical University, Beijing, China; Gani, Y., Hospital Sungai Buloh, Sungai Buloh, Malaysia, ; Mave, V., BJ Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India; Ross, J., TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand; Avihingsanon, A., HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Ly, P.S.; Khol, V.; Zhang, F.J.; Zhao, H.X.; Han, N.; Lee, M.P.; Li, P.C.K.; Kwong, T.S.; Li, T.H.; Kumarasamy, N.; Ezhilarasi, C.; Pujari, S.; Joshi, K.; Gaikwad, S.; Chitalikar, A.; Sangle, S.; Mave, V.; Marbaniang, I.; Nimkar, S.; Merati, T.P.; Wirawan, D.N.; Yuliana, F.; Yunihastuti, E.; Widhani, A.; Maria, S.; Karjadi, T.H.; Tanuma, J.; Oka, S.; Nishijima, T.; Choi, J.Y.; Na, S.; Kim, J.M.; Gani, Y.M., Hospital Sungai Buloh, Sungai Buloh, Malaysia, ; Rudi, N.B.; Azwa, I., University Malaya Medical Centre, Kuala Lumpur, Malaysia, ; Kamarulzaman, A.; SyedOmar, S.F.; Ponnampalavanar, S.; Ditangco, R.; Pasayan, M.K.; Mationg, M.L.; Chan, Y.J.; Ku, W.W.; Wu, P.C.; Ke, E.; Ng, O.T.; Lim, P.L.; Lee, L.S.; Yap, T.; Ng, O.T.; Avihingsanon, A.; Gatechompol, S.; Phanuphak, P.; Phadungphon, C.; Kiertiburanakul, S.; Phuphuakrat, A.; Chumla, L.; Sanmeema, N.; Chaiwarith, R.; Sirisanthana, T.; Praparattanapan, J.; Nuket, K.; Khusuwan, S., Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand, ; Payoong, P.; Kantipong, P.; Kambua, P.; Pham, T.N.; Nguyen, K.V.; Nguyen, D.T.H.; Nguyen, D.T.; Do, C.D.; Ngo, A.V.; Nguyen, L.T.; Sohn, A.H.; Ross, J.L.; Petersen, B.; Law, M.G.; Jiamsakul, A.; Rupasinghe, D.; the TREAT Asia HIV Observational Database of IeDEA Asia-Pacific |
Objectives: We investigated weight changes following antiretroviral therapy (ART) initiation, the development of metabolic syndrome (MetS) and its association with all-cause mortality among Asian adults living with HIV. Methods: Participants enrolled in a regional Asian HIV-infected cohort with weight and height measurements at ART initiation were eligible for inclusion in the analysis. Factors associated with weight changes and incident MetS (according to the International Diabetic Federation (IDF) definition) were analysed using linear mixed models and Cox regression, respectively. Competing-risk regression models were used to investigate the association of MetS with all-cause mortality. Results: Among 4931 people living with HIV (PLWH), 66% were male. At ART initiation, the median age was 34 [interquartile range (IQR) 29–41] years, and the median (IQR) weight and body mass index (BMI) were 55 (48–63) kg and 20.5 (18.4–22.9) kg/m2, respectively. At 1, 2 and 3 years of ART, overall mean (± standard deviation) weight gain was 2.2 (±5.3), 3.0 (±6.2) and 3.7 (±6.5) kg, respectively. Participants with baseline CD4 count ≤ 200 cells/µL [weight difference (diff) = 2.2 kg; 95% confidence interval (CI) 1.9–2.5 kg] and baseline HIV RNA ≥ 100 000 HIV-1 RNA copies/mL (diff = 0.6 kg; 95% CI 0.2–1.0 kg), and those starting with integrase strand transfer inhibitor (INSTI)-based ART (diff = 2.1 kg; 95% CI 0.7–3.5 kg vs. nonnucleoside reverse transcriptase inhibitors) had greater weight gain. After exclusion of those with abnormal baseline levels of MetS components, 295/3503 had incident MetS [1.18 (95% CI 1.05–1.32)/100 person-years (PY)]. The mortality rate was 0.7 (95% CI 0.6–0.8)/100 PY. MetS was not significantly associated with all-cause mortality in the adjusted model (P = 0.236). Conclusions: Weight gain after ART initiation was significantly higher among those initiating ART with lower CD4 count, higher HIV RNA and an INSTI-based regimen after controlling for baseline BMI. Greater efforts to identify and manage MetS among PLWH are needed. © 2021 British HIV Association |
all-cause mortality; Asian people living with HIV; HIV/AIDS; metabolic syndrome; weight gain |
|
John Wiley and Sons Inc |
14642662 |
|
34816562 |
Article |
Q1 |
1530 |
2201 |
|
|
665 |
Atmakusuma T.D., Nasution I.R., Sutandyo N. |
57216961785;8259214700;26028099200; |
Oxidative stress (Malondialdehyde) in adults beta-thalassemia major and intermedia: Comparison between before and after blood transfusion and its correlation with iron overload |
2021 |
International Journal of General Medicine |
14 |
|
|
6455 |
6462 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119614825&doi=10.2147%2fIJGM.S336805&partnerID=40&md5=31da8ca15b655debd14557088a36df4a |
Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Division of Hematology-Medical Oncology, Department of Internal Medicine, Gatot Soebroto Army Hospital Jakarta/Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Hematology-Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital Jakarta/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia |
Atmakusuma, T.D., Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Nasution, I.R., Division of Hematology-Medical Oncology, Department of Internal Medicine, Gatot Soebroto Army Hospital Jakarta/Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sutandyo, N., Division of Hematology-Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital Jakarta/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia |
Background: Iron overload is a major problem in both transfusion-dependent (TDT) and non-transfusion-dependent thalassemia (NTDT). It has been known to increase oxidative stress. Meanwhile, blood transfusion as main therapy for thalassemia increases iron overload. One of the markers of oxidative stress is malondialdehyde (MDA). This study aims to provide data on MDA levels in adult thalassemia patients, and to compare the levels before and after transfusion in patients with TDT and NTDT. Methods: This is a cross-sectional, pre-post study in adult patients with thalassemia major and intermedia that received blood transfusion with or without iron-chelating agents in Cipto Mangunkusumo Hospital. Blood samples were taken immediately before the transfusion and one day after. Serum ferritin (SF) assays were conducted by electrochemiluminescence immunoassay method, while transferrin saturation (TS) was calculated by dividing serum iron by the binding capacity. Subsequently, plasma MDA levels assays were performed using the Wills method, and data analysis was conducted using the t-test/Mann–Whitney and Pearson/Spearman correlation test, depending on the data distribution. Results: The 63 respondents recruited consist of 51 TDT and 12 NTDT patients, and their median plasma MDA level before and after transfusion was 0.49 µmol/L and 0.45 µmol/L, respectively. Before transfusion, there was no correlation between SF and MDA, and TS and MDA levels. After the transfusion, there was no correlation between, SF and MDA, or TS and MDA levels. Conclusion: There is no significant difference in MDA levels before and after transfusion. Although blood transfusion increases the iron load in thalassemia patients, there was no increase in median MDA level after transfusion. Meanwhile, there was no correlation between markers of iron overload and MDA level in thalassemia patients both before and after transfusion. © 2021 Atmakusuma et al. This work is published and licensed by Dove Medical Press Limited. |
Iron overload; Malondialdehyde; Non-transfusion dependent thalassemia; Oxidative stress; Transfusion-dependent thalassemia |
deferasirox; deferiprone; deferoxamine; ferritin; malonaldehyde; adult; aged; Article; blood transfusion; controlled study; cross-sectional study; female; ferritin blood level; hemoglobin E-beta thalassemia; human; Indonesia; iron chelation; iron overload; major clinical study; male; non transfusion dependent thalassemia; oxidative stress; thalassemia major; transferrin saturation; transfusion dependent thalassemia |
Dove Medical Press Ltd |
11787074 |
|
|
Article |
Q2 |
722 |
6874 |
|
|
666 |
Sukrisman L., Sinto R. |
8661764000;36099377100; |
Coagulation profile and correlation between D-dimer, inflammatory markers, and COVID-19 severity in an Indonesian national referral hospital |
2021 |
Journal of International Medical Research |
49 |
11 |
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119613636&doi=10.1177%2f03000605211059939&partnerID=40&md5=c946e5b0ffec2b5ef4b8bd521da19dbf |
Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia; Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia |
Sukrisman, L., Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia; Sinto, R., Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia |
Background: Coagulopathy and inflammation are associated with coronavirus disease 2019 (COVID-19) severity. This study assessed D-dimer concentration and its correlation with inflammatory markers and COVID-19 severity. Methods: This was a retrospective cross-sectional study involving 194 COVID-19 cases, with the severity of infection graded in accordance with the World Health Organization (WHO) guidelines. We measured D-dimer, C-reactive protein (CRP), and ferritin on admission and determined the cutoff values for D-dimer and CRP and evaluated the correlation between D-dimer and CRP and ferritin. Results: Median D-dimer, CRP, and ferritin concentrations were 2240 µg/L, 73.2 mg/L, and 1173.8 µg/mL, respectively. The highest median D-dimer value was seen in mild and moderate acute respiratory distress syndrome (ARDS). The highest ferritin concentration was seen in severe ARDS. There was a significant correlation between D-dimer value and CRP (r = 0.327), but no significant correlation between D-dimer and ferritin (r = 0.101). The area under the receiver operating characteristic curve (AUC) for the combination of CRP ≥72.65 mg/L and D-dimer ≥1250 µg/L as a marker of COVID-19 severity was 0.722 (95% confidence interval (CI): 0.615–0.781). Conclusion: The combination of CRP ≥72.65 mg/L and D-dimer ≥1250 µg/L can be used as marker of COVID-19 severity, with moderate accuracy. © The Author(s) 2021. |
acute respiratory distress syndrome; C-reactive protein; Coronavirus disease 2019; correlation; D-dimer; ferritin; inflammation; severity |
biological marker; fibrin degradation product; fibrin fragment D; cross-sectional study; hospital; human; Indonesia; patient referral; retrospective study; severity of illness index; Biomarkers; COVID-19; Cross-Sectional Studies; Fibrin Fibrinogen Degradation Products; Hospitals; Humans; Indonesia; Referral and Consultation; Retrospective Studies; SARS-CoV-2; Severity of Illness Index |
SAGE Publications Ltd |
03000605 |
|
34796762 |
Article |
Q3 |
421 |
11626 |
|
|
667 |
Lesmana C.R.A., Paramitha M.S., Gani R.A., Lesmana L.A. |
8977683000;57212562901;23495930300;55920139300; |
The role of endoscopic ultrasound for portal hypertension in liver cirrhosis |
2021 |
Journal of Medical Ultrasonics |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119500644&doi=10.1007%2fs10396-021-01165-4&partnerID=40&md5=72338502ade4f82a944b72db4fee4c65 |
Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia |
Lesmana, C.R.A., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia, Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia; Paramitha, M.S., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Gani, R.A., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Lesmana, L.A., Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia |
Chronic liver disease is still a major problem because disease progression will ultimately lead to liver cirrhosis. Portal hypertension is the hallmark in advanced liver disease management. By establishing portal vein access, endoscopic ultrasound (EUS) has been utilized in various clinical applications. In comparison to standard upper gastrointestinal endoscopy, EUS-Doppler has been shown to be a better modality for detecting esophageal and gastric varices along with peri-esophageal collateral veins, para-esophageal collateral veins, and perforating veins, and may be used to objectively predict the recurrence of bleeding. EUS-guided portal vein catheterization has also been proposed to overcome the limitations of trans-jugular approaches. The combination of EUS-elastography and azygos vein evaluation can also enhance the diagnostic accuracy of each modality. Another well-known implementation of EUS-guided procedures is in the management of ascites; particularly in paracentesis and ascitic fluid analysis. In addition, the most common clinical application of EUS in the treatment of portal hypertension is through vascular therapy or creation of intrahepatic portosystemic shunts. Major drawbacks of EUS mainly revolve around technical difficulties, the high cost of the procedure, as well as the requirement of more studies in humans to evaluate EUS-guided advanced therapeutic modalities in portal hypertension. © 2021, The Author(s), under exclusive licence to The Japan Society of Ultrasonics in Medicine. |
Endoscopic ultrasound; Liver cirrhosis; Portal hypertension |
|
Springer |
13464523 |
|
|
Review |
#N/A |
#N/A |
#N/A |
|
|